Modern alternative approaches to the problem of drug-induced liver injury

Alternatives to Laboratory Animals

Volumn 39, Issue 2, 2011, Pages 103-107

  Balls, Michael ^a  

^a RUSSELL AND BURCH HOUSE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEFAZODONE; XENOBIOTIC AGENT;

BIOREACTOR; CALCIUM HOMEOSTASIS; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; EMBRYONIC STEM CELL; EXTRACELLULAR MATRIX; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HIGH RISK POPULATION; HIGH THROUGHPUT SCREENING; HUMAN; LAB ON A CHIP; LIVER CELL; LIVER CELL CULTURE; LIVER METABOLISM; LIVER TOXICITY; MICROFLUIDICS; MITOCHONDRIAL TOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TOXIC HEPATITIS; TOXICITY TESTING;

EID: 79957988797     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119291103900205     Document Type: Editorial

References (20)

1. Blaauboer, B.J., Boobis, A.R., Castell, J.V., Coecke, S., Groothuis, G.M.M., Guillouzo, A., Hall, T.J., Hawksworth, G.M., Lorenzen, G., Milten burger, H.G., Rogiers, V., Skett, P., Villa, P. & Wiebel, F.J. (1994). The practical applicability of hepatocyte cultures in routine testing. The report and recommendations of ECVAM Work shop 1. ATLA 22, 231-241.
2. Issa, A.M., Phillips, K.A., Van Bebber, S., Nida marthy, H.G., Lasser, K.E., Haas, J.S., Alldredge, B.K., Wachter, R.M. & Bates, D.W. (2007). Drug withdrawals in the United States: A systematic review of the evidence and analysis of trends. Current Drug Safety 2, 177-185.
3. Mandenius, C-F., Andersson, T.B., Alves, P.M., Batzl-Hartmann, C., Björquist, P., Carrondo, M.J.T., Chesne, C., Coecke, S., Edsbagge, J., Fred riksson, J.M., Gerlach, J.C., Heinzle, E., Ingelman-Sundberg, M., Johansson, I., Küppers-Munther, B., Müller-Vieira, U., Noor, F. & Zeilinger, K. (2011). Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project. ATLA 39, 147-171.
4. Aithal, G.P. (2010). Mind the gap. ATLA 38, Suppl. 1, 1-4.
5. Balls, M., Combes, R. & Bhogal, N., ed. (2011). New Technologies for Toxicity Testing. Austin, TX, USA: Landes Bioscience, in press.
6. Balls, M., Bennett, A. & Kendall, D. (2011). Trans - lation of new technologies in biomedicines: Shaping the road from basic research to drug development and clinical application - and back again. In Pharmaceutical Biotechnology - A Comprehensive Handbook, 2nd edn (ed. O. Kayser & H. Warzecha). Weinhein, Germany: Wiley VCH, in press.
7. Hudson, M. & Balls, M. (2011). Ethics and regulation in the use of laboratory animals. In Implant Dentistry Research Guide: Basic, Translational and Experimental Clinical Research (ed. A. Ballo). Hauppauge, NY, USA: Nova Science Publishers, in press.
8. BéruBé, K.A. (2011). Alternatives for lung research: Stuck between a rat and a hard place. ATLA 39, 121-130.
9. Kanebratt, K.P. & Andersson, T.B. (2008). Evaluation of HepaRG cells as an in vitro model for human drug metabolism. Drug Metabolism & Disposition 36, 1444-1452. (Pubitemid 351929328)
10. Sullivan, G.J., Hay, D.C., Park, I.H., Fletcher, J., Hannoun, Z., Payne, C.M., Dalgetty, D., Black, J.R., Ross, J.A., Samuel, K., Wang, G., Daley, G.Q., Lee, J.H., Church, G.M., Forbes, S.J., Iredale, J.P. & Wilmut, I. (2010). Gen eration of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 51, 329-335.
11. Marx, U. (2011). Trends in cell culture technology. In New Technologies for Toxicity Testing (ed. M. Balls, R. Combes & N. Bhogal). Austin, TX, USA: Landes Bioscience, in press.
12. Baxter, G.T. (2009). Hurel™ - an in vivo-surrogate assay platform for cell-based studies. ATLA 37, Suppl. 1, 11-18.
13. Li, A.P. (2009). The use of the Integrated Dis crete Multiple Organ Co-culture (IdMOC®) system for the evaluation of multiple organ toxicity. ATLA 37, 377-385.
14. Sbrana, T. & Ahluwalia, A. (2011). Engineering Quasi-VivoTM in-vitro organ models. In New Technologies for Toxicity Testing (ed. M. Balls, R. Combes & N. Bhogal). Austin, TX, USA: Landes Bioscience, in press.
15. Wen, Y., Zhang, X. & Yang, S-T. (2011). Medium to high throughput screening: Microfabrication and chip-based technology. In New Technologies for Toxicity Testing (ed. M. Balls, R. Combes & N. Bhogal). Austin, TX, USA: Landes Bio science, in press.
16. Anon. (2011). The DILI-sim initiative. Research Triangle Park, NC, USA: Hamner-UNC Inst itute for Drug Safety Sciences. Available at: http://www.the-hamner.org/content/DILI-sim-WebEx-4-7-2011.pdf (Accessed 14.04.11).
17. Anon. (2011). Drug-induced liver injury. Liver pool, UK: MRC Centre for Drug Safety Studies. Available at: http://www.liv.ac.uk/drug-safety/research/ research-areas/liver-injury.htm (Acc essed 14.04.11).
18. Daly, A.K., Donaldson, P.T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M.J., Goldstein, D.B., John, S., Nelson, M.R., Graham, J., Park, B.K., Dillon, J.F., Bernal, W., Cordell, H.J., Pirmohamed, M., Aithal, G.P. & Day, C.P. (2009). HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics 41, 816-819.
19. Gamazon, E.R., Huang, R.S., Cox, N.J. & Dolan, M.E. (2010). Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proceedings of the National Academy of Sciences of the USA 107, 9287-9292.
20. Yang, T-P., Beazley, C., Montgomery, S.B., Dimas, A.S., Gutierrez-Arcelus, M., Stranger, B.E., Deloukas, P. & Dermitzakism, E.T. (2010). Genevar: A database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 26, 2474-2476.